RGCC and diffuse midline glioma: CDKN2A is a cell cycle regulator that mediates progression of the cell cycle past the G1 checkpoint and is frequently deleted or silenced via methylation in cancer, including diffuse midline glioma (DMG), where it has been shown in murine models to be downregulated by the K27M mutation [8, 35, 40].